Document Detail


Re-emergence of colistin in today's world of multidrug-resistant organisms: personal perspectives.
MedLine Citation:
PMID:  18549335     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Infections due to multidrug-resistant Gram-negative bacteria (including Acinetobacter baumannii, Pseudomonas aeruginosa, and Klebsiella pneumoniae) are being reported with increasing frequency from various parts of the world. OBJECTIVE: To share personal perspectives on the clinical use of colistin based on the available evidence reported in the literature as well as on knowledge obtained through our clinical experience with the use of colistin in a considerable number of patients during the past 7 years. METHODS: Literature review and personal experience. RESULTS/CONCLUSION: During the last decade, clinicians in several countries have resorted to colistin (polymyxin E), an antibiotic that has been shown to be clinically effective and acceptably safe for intravenous, aerosolized, and intrathecal/intraventricular administration. However, more data are needed to answer important clinical questions, including the appropriate colistin dosage, comparison of colistin monotherapy with combination therapy, and the possible preventive and therapeutic role of aerosolized colistin.
Authors:
Matthew E Falagas; Petros I Rafailidis
Related Documents :
17422195 - Bovine postparturient hemoglobinuria: a review of the literature.
23560565 - The value of β-blockers administration during recovery phase of dobutamine stress echo...
1799735 - Platypnea-orthodeoxia: an unusual indication for surgical closure of a patent foramen o...
12425515 - Combined false hyperkalemia and hypocalcemia due to specimen contamination during routi...
1888505 - Papillary carcinoma in thyroglossal duct remnants.
16380435 - Catatonic schizophrenia and the use of memantine.
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Expert opinion on investigational drugs     Volume:  17     ISSN:  1744-7658     ISO Abbreviation:  Expert Opin Investig Drugs     Publication Date:  2008 Jul 
Date Detail:
Created Date:  2008-06-13     Completed Date:  2008-08-12     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9434197     Medline TA:  Expert Opin Investig Drugs     Country:  England    
Other Details:
Languages:  eng     Pagination:  973-81     Citation Subset:  IM    
Affiliation:
Alfa Institute of Biomedical Sciences (AIBS), 9 Neapoleos Street, 15123 Marousi, Athens, Greece. m.falagas@aibs.gr
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Chemistry, Pharmaceutical
Colistin / pharmacology*
Drug Resistance, Multiple / drug effects*
Drug Tolerance
Drug Toxicity
Humans
Polymyxins / pharmacology
Chemical
Reg. No./Substance:
0/Polymyxins; 1066-17-7/Colistin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Antisense technology for the prevention or the treatment of cardiovascular disease: the next blockbu...
Next Document:  Agents that block advanced glycation end product (AGE)-RAGE (receptor for AGEs)-oxidative stress sys...